Switching first-line targeted therapy after not reaching low disease activity within 6 months is superior to conservative approach: a propensity score-matched analysis from the ATT...

by Lucie Nekvindová, Jiří Vencovský, Karel Pavelka, Pavel Horák, Zlatuše Křístková, Jakub Závada
Published 2021-01-01

Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study.

by Jana Hurnakova, Hana Hulejova, Jakub Zavada, Petra Hanova, Martin Komarc, Herman Mann, Martin Klein, Olga Sleglova, Marta Olejarova, Sarka Forejtova, Olga Ruzickova, Jiri Vencovsky, Karel Pavelka, Ladislav Senolt
Published 2017-01-01

Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission.

by Jana Hurnakova, Hana Hulejova, Jakub Zavada, Martin Komarc, Petra Hanova, Martin Klein, Herman Mann, Olga Sleglova, Marta Olejarova, Sarka Forejtova, Olga Ruzickova, Jiri Vencovsky, Karel Pavelka, Ladislav Senolt
Published 2016-01-01